Preventing prolonged seizures from progressing to status epilepticus. Prof. Matthew Walker speaks to Oruen for this expert interview.
Article Information
Volume 12 Issue 1 August 2026, pages 18-23
DISCLOSURE: Matthew Walker has consulted for Angelini Pharma, EpilepsyGtX, and UCB pharma and has received honoraria from Angelini Pharma, Eisai, and UCB pharma. He is Chair of Trustees of Epilepsy Research Institute. He was a founder of and owns shares in EpilepsyGtx, a company developing gene therapies for epilepsy. MCW also holds patents for epilepsy treatments.
ACKNOWLEDGEMENTS: This article was developed with editorial support from Oruen Ltd. and funded by Neuraxpharm
CORRESPONDING AUTHOR: Matthew Walker – m.walker@ucl.ac.uk
Abstract:
Hello, my name is Professor Matthew Walker. I’m a Professor of Neurology at the UCL Queen Square Institute of Neurology and at the National Hospital for Neurology and Neurosurgery, Queen Square in London. I’m a practising clinician and I see patients mainly with drug resistant epilepsy. I have a clinical and experimental laboratory where I study not only new medications but also the consequences and the treatment of status epilepticus.
Keywords:
Epilepsy; Prolonged seizures; Status epilepticus; Rescue medication; Buccal midazolam; Diazepam; Seizure action plansFollow Us
Newsletter
Keep up to date with our latest
articles and journals
0 Comments